Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8464579 | 0.84 | EPHX1 (0.46) | EPHX1MAPTNPSR1RAB9AALDH1A1 | |
| SCHEMBL2050427 | 0.84 | — | — | |
| SCHEMBL1498382 | 0.80 | BTK (0.53) | EPHX1KMT2AKCNA3EPHX2 | |
| SCHEMBL1561255 | 0.80 | NFKB1 (0.45) | EPHX1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL5949566 | 0.80 | HSD11B1 (0.42) | EPHX1NPSR1RAB9AALDH1A1NPC1 | |
| SCHEMBL423315 | 0.79 | — | — | |
| SCHEMBL868764 | 0.79 | EPHX1 (0.59) | EPHX1MAPTNPSR1RAB9AALDH1A1 | |
| SCHEMBL20641819 | 0.77 | — | — | |
| SCHEMBL1561037 | 0.77 | ATM (0.47) | EPHX1MAPTMEN1KMT2ARAB9A | |
| SCHEMBL23735487 | 0.77 | EPHX2 (0.56) | EPHX1MAPTRAB9AALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399461-B2 | Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for production of same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-03-19 | — | — | US | claimed |
| US-20110136805-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR PRODUCTION OF SAME | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-09 | — | — | US | claimed |
| EP-2091925-B1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR PRODUCTION OF SAME | BOEHRINGER INGELHEIM INT (DE) | 2011-04-06 | — | — | EP | claimed |
| EP-2091925-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR PRODUCTION OF SAME | Boehringer Ingelheim International GmbH (DE) | 2009-08-26 | — | — | EP | claimed |
| EP-1966189-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-09-10 | — | — | EP | claimed |
| WO-2008055854-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR PRODUCTION OF SAME | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-15 | — | — | WO | claimed |
| EP-1921070-A1 | Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2008-05-14 | — | — | EP | claimed |
| WO-2007068552-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | WO | claimed |
| US-20070135463-A1 | Bicyclic heterocycles, drugs containing said compounds, the use thereof and method for preparing same | HIMMELSBACH FRANK | 2007-06-14 | — | — | US | claimed |
| US-8399461-B2 | Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for production of same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-03-19 | — | — | US | disclosed |
| EP-2373329-A2 | USE OF EPIDERMAL GROWTH FACTOR INHIBITORS IN THE TREATMENT OF VIRAL INFECTION | The Regents of the University of California (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20110236349-A1 | Use of Epidermal Growth Factor Inhibitors in the Treatment of Viral Infection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2011-09-29 | — | — | US | disclosed |
| US-20110136805-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR PRODUCTION OF SAME | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-09 | — | — | US | disclosed |
| EP-2091925-B1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR PRODUCTION OF SAME | BOEHRINGER INGELHEIM INT (DE) | 2011-04-06 | — | — | EP | disclosed |
| EP-1505063-A1 | BENZIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-02-09 | — | — | EP | disclosed |
| WO-2004094404-A1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2004-11-04 | — | — | WO | disclosed |
| US-20040204426-A1 | 4-Imidazolin-2-one compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-10-14 | — | — | US | disclosed |
| US-20040044056-A1 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-03-04 | — | — | US | disclosed |
| US-20030236267-A1 | Benzimidazole derivatives | MSD K.K. (JP) | 2003-12-25 | — | — | US | disclosed |
| EP-1342717-A1 | BENZIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136805-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR PRODUCTION OF SAME | BPHL, CYP11B2, CYP11B1 | EPHX1 3599/4885MAPT 498/4885MEN1 1093/4885 |
| US-20070135463-A1 | Bicyclic heterocycles, drugs containing said compounds, the use thereof and method for preparing same | BPHL, CYP11B2, CYP11B1 | EPHX1 2805/4885MAPT 410/4885MEN1 1036/4885 |
| US-20030236267-A1 | Benzimidazole derivatives | OPRL1, GPR119, NPBWR1 | EPHX1 4285/4885MAPT 748/4885MEN1 1634/4885 |
| US-20040204426-A1 | 4-Imidazolin-2-one compounds | NR3C1, NR3C2, SCN1B | EPHX1 3905/4885MAPT 4542/4885MEN1 728/4885 |
| US-20110236349-A1 | Use of Epidermal Growth Factor Inhibitors in the Treatment of Viral Infection | EGFR, HDGF, HGF | EPHX1 2799/4885MAPT 3293/4885MEN1 1955/4885 |
| US-20040044056-A1 | Benzimidazole derivatives | GPR119, OPRL1, INSR | EPHX1 4704/4885MAPT 400/4885MEN1 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.